Federal officials have approved Journavx by Vertex Pharmaceuticals as a new non-opioid pain relief option following surgery or injury. This marks the first significant advancement in pain management in two decades. The FDA green-lighted Journavx despite its modest effectiveness compared to existing medications like a common opioid-acetaminophen combination. Priced at $15.50 per pill, Journavx is significantly more expensive than generic opioids, highlighting the challenges of developing effective new pain treatments amid rising opioid overdose concerns. Vertex's innovative mechanism targets pain signal proteins instead of binding to brain receptors.
The U.S. FDA approved Vertex Pharmaceuticals' Journavx as a new pain medication, aiming to avoid addiction risks linked to traditional opioids.
Vertex's Journavx is the first new approach to pain treatment in over two decades, providing an alternative to opioids and common over-the-counter medications.
Despite its approval, the drug's modest effectiveness raises concerns about its competitive edge against existing pain management options.
Vertex's new drug works by blocking pain signal-triggering proteins rather than the traditional opioid method of binding to brain receptors.
Collection
[
|
...
]